Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease
Abstract
To determine the inflammatory analytes that predict clinical progression and evaluate their performance against biomarkers of neurodegeneration.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2020
- Source ID
- 10.1002/acn3.51109
Entities
People
- Aaron Bonner‐jackson
- Akshay Pai
- Bruce T. Lamb
- Gurkan Bebek
- Jagan A Pillai
- James B. Leverenz
- James Bena
- Lauge Sørensen
- Lei Kou
- Lynn M. Bekris
- Mads Neilsen
- Mark R. Chance
- Stephen M Rao
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Case Western Reserve University
- Chiron Corporation
- Cleveland Clinic
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Indiana University
- Innogenetics
- Lou Ruvo Center for Brain Health
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Copenhagen